Optimising the sequence of novel therapies from early relapse in multiple myeloma

In these short videos, Professors Evangelos Terpos and Hermann Einsele share key insights from their lecture on multiple myeloma at the prestigious 6th European Myeloma Network (EMN) Meeting, sponsored by Menarini Stemline.

Key topics include:

• Individualised treatment in early relapse in multiple myeloma
• Optimising the sequence of novel therapies from early relapse

Clinical takeaways

• Although therapeutic advances in MM have improved outcomes, this has generated a wide range of patient profiles at early relapse  
• There is a need for new targets/new drugs with a different MoA 
• Many novel immunotherapies for R/R MM, including CAR-T cell therapy, bispecific antibodies and ADCs, are coming to earlier lines of treatment 
• Selinexor is a first-in-class, oral XPO1 inhibitor with a unique MoA  
• SVd may be a suitable treatment option for early relapsed patients previously treated with lenalidomide and daratumumab, as it offers a double MoA switch 
• In the real-world setting, SVd is easy to manage with dose reductions and prophylactic use of drugs, resulting in good efficacy outcomes
• To improve patient survival rates, we need to better understand the optimal sequencing of selinexor combinations across the novel immune therapies